Psychiatric comorbidities, including mood, anxiety, and psychotic disorders, are common in
epilepsy, often occurring at rates 2–3-fold or higher than in the general population without …

The purpose of this article is to review the topic of interictal psychiatric comorbidity among
adult patients with chronic epilepsy, focusing specifically on those studies that have used …

В руководстве представлены результаты 60-летней работы автора в области детской
и взрослой неврологии и эпилептологии. Впервые эпилептология представлена в …

With the introduction of several new antiepileptic drugs into clinical practice, renewed
attention has been focussed on treatment-emergent adverse effects, including mood …

The classification of psychiatric disorders in epilepsy has evolved considerably from the first
attempts in the 19th century. A dedicated subcommission of the ILAE Commission on …

Psychotic disorders represent a relatively rare but serious comorbidity in epilepsy. Current
epidemiological studies are showing a point prevalence of 5.6% in unselected samples of …

Background Purified cannabidiol is a new antiepileptic drug that has recently been
approved for use in patients with Lennox–Gastaut and Dravet syndromes, but most …

With almost 100years of clinical experience, antiepileptic drugs (AEDs) remain the mainstay
of epilepsy treatment. They suppress epileptic seizures by acting on a variety of mechanisms …

This report reviews behavioral adverse events occurring among adults receiving
levetiracetam (LEV) or placebo who participated in short-term, placebo-controlled studies in …

At least 50–60% of patients with epilepsy develop psychiatric disturbances, particularly
mood, anxiety, and psychotic disorders. This article, aimed at the non-psychiatric clinician …